• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner.

    Sonder Capital

    Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered the use of person-generated health data and connected devices in decentralized research and large-scale health programs. Prior to Evidation, Kilpatrick held leadership roles in medical device and molecular diagnostic companies, including multiple roles at Guidant Corporation such as Research Fellow, Director of Research and Technology Development, and Director of New Ventures, prior to its acquisition by Boston Scientific. She is the co-Founder of MedtechWomen and the MedtechVision Conference, held annually in Silicon Valley and currently serves on the Board of Directors at Sleep Number (NASDAQ:SNBR), NextGen Jane, and Sutter Health, one of the largest and most innovative healthcare systems in the US providing care to millions throughout California.

    Kilpatrick's background in medical devices coupled with her expertise in digital health technology will strengthen the Sonder team's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI.

    "I'm excited to join the Sonder team and be a part of creating what's next in medtech," said Kilpatrick. "There is no doubt that the sector has driven better patient outcomes for decades. But I believe medtech is entering a new era where novel technologies will drive entirely new standards of care and transform both the clinician and patient experience in ways we are just beginning to imagine."

    "We couldn't be more excited to welcome Deb to the Sonder team," said Kate Garrett, Managing Partner of Sonder Capital. "The future of the medtech industry will become a convergence of big data, AI and connected devices, creating unprecedented opportunities to improve healthcare. With a career deeply rooted in all of these areas, Deb brings unparalleled expertise to our team. Beyond that, Deb has been a champion of women leaders in the healthcare sector her entire career, something I and thousands of others have benefitted from. We are thrilled to be working side by side with her."

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D

    Contacts

    Marisa Meehan, Sonder Capital

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deborah-kilpatrick-joins-sonder-capital-as-its-newest-venture-partner-302288301.html

    SOURCE Sonder Capital

    Get the next $ISRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has been appointed as the new Venture Partner at Sonder Capital?

      Deborah Kilpatrick has joined Sonder Capital as a Venture Partner, bringing extensive experience in healthcare technology and leadership roles in the medtech sector.

    • What was Deborah Kilpatrick's previous role before joining Sonder Capital?

      Kilpatrick was previously the CEO of Evidation Health, where she led efforts in utilizing person-generated health data and connected devices for research and health programs.

    • What is Deborah Kilpatrick's educational background?

      Kilpatrick holds a Ph.D. in mechanical engineering with a focus on bioengineering from Georgia Tech and has been involved in various leadership roles in medical device companies, including Guidant Corporation.

    • Why is Deborah Kilpatrick's addition significant for Sonder Capital?

      Joining Sonder Capital enhances their investment capabilities in the rapidly evolving medtech sector, especially in areas integrating multi-modal health data and AI.

    • What vision did Deborah Kilpatrick express about the future of the medtech sector?

      Kilpatrick emphasized that medtech is entering a new era where innovative technologies will set new standards of care and significantly enhance patient and clinician experiences.

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SNBR
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    More analyst ratings

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Interim CFO Ryder Robert P bought $102,160 worth of shares (15,000 units at $6.81) (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    8/4/25 4:05:05 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Director Eyler Phillip bought $74,942 worth of shares (8,300 units at $9.03), increasing direct ownership by 65% to 20,972 units (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    5/14/25 4:01:01 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    SEC Filings

    View All

    Sleep Number Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sleep Number Corp (0000827187) (Filer)

    1/28/26 8:01:37 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Intuitive Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    1/22/26 4:05:12 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    1/14/26 8:58:49 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Da Vinci 5 Cleared for Cardiac Procedures

    SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.         Cardiovascular disease remains the leading cause of death worldwide, claiming nearly 18 million lives each year.i More than two million patients worldwide undergo open heart surgery annuallyii, with most procedures requiring a sternotomy, an approach that involves splitting

    1/26/26 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    20 Million Patients Benefit from da Vinci Surgery Globally

    SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that more than 20 million patients worldwide have been operated on by surgeons using da Vinci surgical systems. The milestone was reached as of the end of 2025, with more than 3.1 million da Vinci procedures performed last year alone. This achievement reflects the continued adoption of, and expanded patient access to, Intuitive's minimally invasive technology. "This achievement is a direct result of the dedication of surgeons and care teams around the globe to provide the best possible care for their pat

    1/23/26 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leonard Keith R disposed of 369 shares, decreasing direct ownership by 50% to 370 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:45:03 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by SVP & Chief Mfg and Supply Cha Brosius Mark

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:28:38 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by EVP & Chief Legal and Complian Loeb Gary

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:24:32 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Intuitive Surgical with a new price target

    TD Cowen initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $660.00

    1/27/26 8:46:58 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    UBS initiated coverage on PROCEPT BioRobotics with a new price target

    UBS initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $62.00

    12/12/25 8:54:55 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Surgical downgraded by Citigroup with a new price target

    Citigroup downgraded Intuitive Surgical from Buy to Neutral and set a new price target of $635.00

    12/11/25 8:53:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Sleep Number Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted an equity award on December 15, 2025, as a material inducement to the employment of the company's newly-hired Executive Vice President and Chief Financial Officer, Amy O'Keefe. As previously disclosed, in connection with the appointment of O'Keefe as Executive Vice President and Chief Financial Officer effective December 8, 2025, Sleep Number granted O'Keefe an employment inducement award consisting of 69,742 shares in a time-vested restricted stock unit award that vests in three equal installments on each anniversary from the date of grant. The grants are subject to continued employment and the terms of the award agree

    12/15/25 4:01:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Sleep Number Names Amy O'Keefe as CFO

    O'Keefe Brings Proven Expertise in Driving Profitability and Cash Flow in Public and Private Companies Company Reaffirms Full Year 2025 Financial Guidance Sleep Number Corporation (NASDAQ:SNBR) today announces Amy O'Keefe as its next Chief Financial Officer (CFO), effective December 8, 2025. Interim CFO Bob Ryder will remain with the company to ensure a smooth transition through December 12, 2025. "Since joining Sleep Number, we've taken decisive action to stabilize the business and position it for sustainable growth. Our strategy is clear and centered on our strong brand, differentiated products, and simplified operating model to deliver value for shareholders, customers, and team membe

    12/2/25 7:30:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Announces Fourth Quarter Earnings

    SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025. Q4 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.The Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 i

    1/22/26 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results

    SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational Highlights Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%. Average da Vinci system utilization increased 4%

    1/14/26 9:05:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    12/2/24 5:07:30 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    11/25/24 6:54:27 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care